8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 4, 2026·SEC
Material company update
Nov 21, 2025·SEC
Eli Lilly and Company(LLY)Earnings, Financials & Key Ratios
LLY•NYSE
$988.19
$933.66B mkt cap·43.1× P/E·Price updated May 6, 2026
AboutEli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.Show more
- Revenue$65.18B+44.7%
- EBITDA$31.26B+62.2%
- Net Income$20.64B+94.9%
- EPS (Diluted)22.95+96.0%
- Gross Margin83.79%+3.1%
- EBITDA Margin47.96%+12.1%
- Operating Margin45.56%+17.3%
- Net Margin31.66%+34.7%
- ROE101.15%+20.0%
- ROIC41.82%+24.1%
- Debt/Equity1.60-32.1%
- Interest Coverage33.16+92.3%
LLY Key Insights
Eli Lilly and Company (LLY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 78.0%
- ✓Strong 5Y profit CAGR of 27.2%
- ✓Strong Piotroski F-Score: 8/9
- ✓11 consecutive years of dividend growth
- ✓Strong 5Y sales CAGR of 21.6%
- ✓Healthy 5Y average net margin of 22.4%
✗Weaknesses
- ✗Expensive at 33.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LLY Price & Volume
Eli Lilly and Company (LLY) stock price & volume — 10-year historical chart
Loading chart...
LLY Growth Metrics
Eli Lilly and Company (LLY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.56%
5 Years21.58%
3 Years31.69%
TTM47.44%
Profit CAGR
10 Years23.96%
5 Years27.22%
3 Years48.95%
TTM127.57%
EPS CAGR
10 Years26.54%
5 Years28.82%
3 Years51.73%
TTM129.05%
Return on Capital
10 Years25.9%
5 Years33.51%
3 Years39.33%
Last Year46.55%
LLY Recent Earnings
Eli Lilly and Company (LLY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 9/12 qtrs (82%)
Q2 2026Latest
Apr 30, 2026EPS
$8.55
Est $6.97
+22.7%
Revenue
$19.8B
Est $17.8B
+11.1%
Q1 2026
Feb 4, 2026EPS
$7.54
Est $6.91
+9.1%
Revenue
$19.3B
Est $17.9B
+7.5%
Q4 2025
Oct 30, 2025EPS
$7.02
Est $5.69
+23.4%
Revenue
$17.6B
Est $16.1B
+9.6%
Q3 2025
Aug 7, 2025EPS
$6.31
Est $5.60
+12.7%
Revenue
$15.6B
Est $14.7B
+5.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $8.55vs $6.97+22.7% | $19.8Bvs $17.8B+11.1% |
| Q1 2026 | Feb 4, 2026 | $7.54vs $6.91+9.1% | $19.3Bvs $17.9B+7.5% |
| Q4 2025 | Oct 30, 2025 | $7.02vs $5.69+23.4% | $17.6Bvs $16.1B+9.6% |
| Q3 2025 | Aug 7, 2025 | $6.31vs $5.60+12.7% | $15.6Bvs $14.7B+5.8% |
Based on last 12 quarters of dataView full earnings history →
LLY Peer Comparison
Eli Lilly and Company (LLY) competitors in Large diversified branded pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVO | 151.36B | 44.89 | 12.41 | 2.34% | 33.14% | 50.76% | 5.88% | 0.67 |
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
 MRK | 279.49B | 113.16 | 15.54 | 1.18% | 28.12% | 36.14% | 4.42% | 0.96 |
 AZN | 280.97B | 181.24 | 27.71 | 8.63% | 17.19% | 22.24% | 4.19% | 0.61 |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 JNJ | 543.64B | 225.59 | 38.96 | 4.3% | 27.26% | 31.69% | 3.65% | 0.51 |
 NVS | 277.63B | 145.50 | 20.24 | 5.97% | 24.14% | 31.42% | 6.37% | 0.80 |
Compare LLY vs Peers
Eli Lilly and Company (LLY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LLY Income Statement
Eli Lilly and Company (LLY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 19.97B | 21.49B | 22.32B | 24.54B | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B | 72.25B |
| Revenue Growth % | -5.88% | 7.61% | 3.84% | 9.95% | 15.4% | 0.79% | 19.56% | 32% | 44.7% | 47.44% |
| Cost of Goods Sold | 4.45B | 4.68B | 4.72B | 5.48B | 7.31B | 6.63B | 7.08B | 8.42B | 10.56B | 11.92B |
| COGS % of Revenue | 22.27% | 21.78% | 21.15% | 22.34% | 25.82% | 23.23% | 20.75% | 18.69% | 16.21% | - |
| Gross Profit | 15.53B▲ 0% | 16.81B▲ 8.3% | 17.6B▲ 4.7% | 19.06B▲ 8.3% | 21.01B▲ 10.2% | 21.91B▲ 4.3% | 27.04B▲ 23.4% | 36.62B▲ 35.4% | 54.62B▲ 49.1% | 60.33B▲ 0% |
| Gross Margin % | 77.73% | 78.22% | 78.85% | 77.66% | 74.18% | 76.77% | 79.25% | 81.31% | 83.79% | 83.51% |
| Gross Profit Growth % | 0.09% | 8.28% | 4.68% | 8.29% | 10.23% | 4.31% | 23.41% | 35.44% | 49.12% | - |
| Operating Expenses | 11.28B | 10.79B | 11.6B | 11.85B | 13.07B | 13.26B | 16.25B | 19.12B | 24.92B | 27.2B |
| OpEx % of Revenue | 56.46% | 50.18% | 51.97% | 48.27% | 46.16% | 46.45% | 47.63% | 42.45% | 38.23% | - |
| Selling, General & Admin | 6.18B | 5.73B | 6B | 5.87B | 6.14B | 6.07B | 6.94B | 8.13B | 11.09B | 11.67B |
| SG&A % of Revenue | 30.94% | 26.68% | 26.9% | 23.92% | 21.69% | 21.26% | 20.34% | 18.05% | 17.02% | - |
| Research & Development | 5.1B | 5.05B | 5.59B | 5.98B | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B | 14.11B |
| R&D % of Revenue | 25.51% | 23.5% | 25.07% | 24.35% | 24.47% | 25.19% | 27.29% | 24.4% | 20.46% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 487.5M | 2M |
| Operating Income | 4.25B▲ 0% | 6.03B▲ 41.8% | 6B▼ 0.4% | 7.21B▲ 20.2% | 7.93B▲ 10.0% | 8.65B▲ 9.1% | 10.79B▲ 24.7% | 17.5B▲ 62.2% | 29.7B▲ 69.7% | 33.14B▲ 0% |
| Operating Margin % | 21.28% | 28.04% | 26.88% | 29.38% | 28.01% | 30.32% | 31.61% | 38.86% | 45.56% | 45.87% |
| Operating Income Growth % | 9.78% | 41.79% | -0.44% | 20.19% | 10.02% | 9.08% | 24.66% | 62.24% | 69.67% | - |
| EBITDA | 5.82B | 7.63B | 7.23B | 8.53B | 9.48B | 10.18B | 12.31B | 19.27B | 31.26B | 34.75B |
| EBITDA Margin % | 29.12% | 35.52% | 32.4% | 34.78% | 33.48% | 35.65% | 36.09% | 42.78% | 47.96% | 48.09% |
| EBITDA Growth % | 8.37% | 31.25% | -5.28% | 18.01% | 11.08% | 7.33% | 21.02% | 56.47% | 62.23% | 57.92% |
| D&A (Non-Cash Add-back) | 1.57B | 1.61B | 1.23B | 1.32B | 1.55B | 1.52B | 1.53B | 1.77B | 1.56B | 1.61B |
| EBIT | 2.53B | 3.92B | 5.67B | 7.59B | 6.5B | 7.14B | 7.04B | 13.46B | 26.37B | 31.52B |
| Net Interest Income | -58.6M | -83.2M | -320.2M | -326.6M | -314.4M | -268.8M | -312.3M | -605.4M | -642M | -778.6M |
| Interest Income | 166.4M | 159.3M | 80.4M | 33M | 25.4M | 62.8M | 173.6M | 175.2M | 153.3M | 105M |
| Interest Expense | 225M | 242.5M | 400.6M | 359.6M | 339.8M | 331.6M | 485.9M | 780.6M | 795.3M | 883.6M |
| Other Income/Expense | -1.95B | -2.35B | -733.5M | 19.1M | -1.78B | -1.85B | -4.23B | -4.82B | -3.96B | -2.01B |
| Pretax Income | 2.3B▲ 0% | 3.68B▲ 59.7% | 5.27B▲ 43.1% | 7.23B▲ 37.3% | 6.16B▼ 14.9% | 6.81B▲ 10.6% | 6.55B▼ 3.7% | 12.68B▲ 93.5% | 25.73B▲ 102.9% | 31.12B▲ 0% |
| Pretax Margin % | 11.54% | 17.12% | 23.59% | 29.46% | 21.74% | 23.85% | 19.21% | 28.15% | 39.48% | 43.08% |
| Income Tax | 2.39B | 529.5M | 628M | 1.04B | 573.8M | 561.6M | 1.31B | 2.09B | 5.09B | 5.85B |
| Effective Tax Rate % | 103.75% | 14.39% | 11.93% | 14.33% | 9.32% | 8.25% | 20.05% | 16.49% | 19.79% | 18.79% |
| Net Income | -204.1M▲ 0% | 3.23B▲ 1683.5% | 8.32B▲ 157.4% | 6.19B▼ 25.5% | 5.58B▼ 9.9% | 6.24B▲ 11.9% | 5.24B▼ 16.1% | 10.59B▲ 102.1% | 20.64B▲ 94.9% | 25.27B▲ 0% |
| Net Margin % | -1.02% | 15.04% | 37.27% | 25.24% | 19.71% | 21.88% | 15.36% | 23.51% | 31.66% | 34.98% |
| Net Income Growth % | -107.46% | 1683.54% | 157.38% | -25.54% | -9.88% | 11.88% | -16.08% | 102.08% | 94.88% | 127.57% |
| Net Income (Continuing) | -86.4M | 3.15B | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B | 25.27B |
| Discontinued Operations | -117.7M | 81.4M | 3.68B | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 75.7M | 1.08B | 92.2M | 183.6M | 175.6M | 125.6M | 91.8M | 79.5M | 0 | 0 |
| EPS (Diluted) | -0.19▲ 0% | 3.13▲ 1747.4% | 8.69▲ 177.6% | 6.47▼ 25.5% | 5.85▼ 9.6% | 6.57▲ 12.3% | 5.80▼ 11.7% | 11.71▲ 101.9% | 22.95▲ 96.0% | 28.21▲ 0% |
| EPS Growth % | -107.63% | 1747.37% | 177.64% | -25.55% | -9.58% | 12.31% | -11.72% | 101.9% | 95.99% | 129.05% |
| EPS (Basic) | -0.19 | 3.14 | 8.69 | 6.47 | 5.85 | 6.57 | 5.83 | 11.76 | 23.00 | - |
| Diluted Shares Outstanding | 1.05B | 1.03B | 957.53M | 956.59M | 953.65M | 950.18M | 903.28M | 904.06M | 898M | 895.9M |
| Basic Shares Outstanding | 1.05B | 1.03B | 957.53M | 956.59M | 953.65M | 950.18M | 899.38M | 900.61M | 898M | 894.5M |
| Dividend Payout Ratio | - | 71.53% | 28.97% | 43.38% | 55.3% | 56.62% | 77.65% | 44.2% | 26.09% | - |
LLY Balance Sheet
Eli Lilly and Company (LLY) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 19.2B | 20.55B | 13.71B | 17.46B | 18.45B | 18.03B | 25.73B | 32.74B | 55.63B | 54.84B |
| Cash & Short-Term Investments | 8.03B | 7.41B | 2.44B | 3.68B | 3.91B | 2.21B | 2.93B | 3.42B | 7.27B | 5.28B |
| Cash Only | 6.54B | 7.32B | 2.34B | 3.66B | 3.82B | 2.07B | 2.82B | 3.27B | 7.16B | 5.28B |
| Short-Term Investments | 1.5B | 88.2M | 101M | 24.2M | 90.1M | 144.8M | 109.1M | 154.8M | 105M | 0 |
| Accounts Receivable | 5.26B | 5.78B | 5.54B | 6.93B | 8.13B | 8.56B | 11.34B | 13.28B | 20.16B | 21.18B |
| Days Sales Outstanding | 96.16 | 98.1 | 90.62 | 103.06 | 104.75 | 109.45 | 121.25 | 107.58 | 112.87 | 98.51 |
| Inventory | 4.46B | 3.1B | 3.19B | 3.98B | 3.89B | 4.31B | 5.77B | 7.59B | 13.74B | 14.53B |
| Days Inventory Outstanding | 365.87 | 241.54 | 246.68 | 264.95 | 193.96 | 237.27 | 297.52 | 329.05 | 474.87 | 394.1 |
| Other Current Assets | 0 | 2.23B | 0 | 0 | 0 | 7.3M | 149.5M | 111.4M | 147M | 13.85B |
| Total Non-Current Assets | 25.78B | 23.36B | 25.58B | 29.17B | 30.35B | 31.46B | 38.28B | 45.98B | 56.85B | 61.74B |
| Property, Plant & Equipment | 8.83B | 8B | 8.4B | 8.68B | 8.99B | 10.14B | 12.91B | 17.1B | 24.68B | 26.54B |
| Fixed Asset Turnover | 2.26x | 2.69x | 2.66x | 2.83x | 3.15x | 2.81x | 2.64x | 2.63x | 2.64x | 3.07x |
| Goodwill | 4.37B | 1.37B | 3.68B | 3.77B | 3.89B | 4.07B | 4.94B | 5.77B | 5.9B | 6.13B |
| Intangible Assets | 4.03B | 1.07B | 6.62B | 7.45B | 7.69B | 7.21B | 6.91B | 6.17B | 6.52B | 7.37B |
| Long-Term Investments | 5.68B | 2.02B | 1.96B | 2.97B | 3.21B | 2.9B | 3.05B | 3.22B | 2.8B | 11.93B |
| Other Non-Current Assets | 2.87B | 8.3B | 2.34B | 3.48B | 4.08B | 4.34B | 4.99B | 5.72B | 6.99B | 26.88B |
| Total Assets | 44.98B▲ 0% | 43.91B▼ 2.4% | 39.29B▼ 10.5% | 46.63B▲ 18.7% | 48.81B▲ 4.7% | 49.49B▲ 1.4% | 64.01B▲ 29.3% | 78.71B▲ 23.0% | 112.48B▲ 42.9% | 116.58B▲ 0% |
| Asset Turnover | 0.44x | 0.49x | 0.57x | 0.53x | 0.58x | 0.58x | 0.53x | 0.57x | 0.58x | 0.65x |
| Asset Growth % | 15.91% | -2.38% | -10.53% | 18.7% | 4.66% | 1.4% | 29.33% | 22.98% | 42.89% | 165.74% |
| Total Current Liabilities | 14.54B | 11.89B | 11.78B | 12.48B | 15.05B | 17.14B | 27.29B | 28.38B | 35.23B | 36.63B |
| Accounts Payable | 1.41B | 1.21B | 1.41B | 1.61B | 1.67B | 1.93B | 2.6B | 3.23B | 5.38B | 5.03B |
| Days Payables Outstanding | 115.77 | 94.11 | 108.64 | 106.95 | 83.38 | 106.29 | 133.94 | 139.99 | 185.85 | 143.54 |
| Short-Term Debt | 3.71B | 1.1B | 1.5B | 8.7M | 1.54B | 1.5B | 6.9B | 5.12B | 1.64B | 4B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7.82B | 3.69B | 3.1B | 9.3B | 10.68B | 3.91B | 16.14B | 7.15B | 28.21B | 27.61B |
| Current Ratio | 1.32x | 1.73x | 1.16x | 1.40x | 1.23x | 1.05x | 0.94x | 1.15x | 1.58x | 1.58x |
| Quick Ratio | 1.01x | 1.47x | 0.89x | 1.08x | 0.97x | 0.80x | 0.73x | 0.89x | 1.19x | 1.19x |
| Cash Conversion Cycle | 346.26 | 245.53 | 228.65 | 261.06 | 215.33 | 240.44 | 284.84 | 296.64 | 401.89 | 349.06 |
| Total Non-Current Liabilities | 18.78B | 21.11B | 24.81B | 28.33B | 24.6B | 21.58B | 25.85B | 36.07B | 50.71B | 48.74B |
| Long-Term Debt | 9.93B | 9.2B | 13.82B | 16.59B | 15.35B | 14.74B | 18.32B | 28.53B | 40.87B | 39.37B |
| Capital Lease Obligations | 0 | 0 | 486.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 1.31B | 2.19B | 2.1B | 1.73B | 87.3M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 8.85B | 10.6B | 8.32B | 9.64B | 7.52B | 6.75B | 7.53B | 7.54B | 9.85B | 38.66B |
| Total Liabilities | 33.31B | 33B | 36.59B | 40.81B | 39.65B | 38.71B | 53.14B | 64.44B | 85.94B | 85.38B |
| Total Debt | 13.65B | 10.3B | 15.8B | 16.6B | 16.88B | 16.24B | 25.23B | 33.64B | 42.5B | 43.37B |
| Net Debt | 7.11B | 2.98B | 13.47B | 12.94B | 13.07B | 14.17B | 22.41B | 30.38B | 35.34B | 38.09B |
| Debt / Equity | 1.17x | 0.94x | 5.86x | 2.85x | 1.84x | 1.51x | 2.32x | 2.36x | 1.60x | 1.60x |
| Debt / EBITDA | 2.35x | 1.35x | 2.19x | 1.94x | 1.78x | 1.60x | 2.05x | 1.75x | 1.36x | 1.25x |
| Net Debt / EBITDA | 1.22x | 0.39x | 1.86x | 1.52x | 1.38x | 1.39x | 1.82x | 1.58x | 1.13x | 1.13x |
| Interest Coverage | 11.24x | 16.18x | 14.15x | 21.11x | 19.12x | 21.53x | 14.49x | 17.24x | 33.16x | 35.68x |
| Total Equity | 11.67B▲ 0% | 10.91B▼ 6.5% | 2.7B▼ 75.3% | 5.83B▲ 115.8% | 9.15B▲ 57.2% | 10.78B▲ 17.7% | 10.86B▲ 0.8% | 14.27B▲ 31.4% | 26.54B▲ 85.9% | 31.2B▲ 0% |
| Equity Growth % | -17.13% | -6.5% | -75.26% | 115.82% | 57.16% | 17.7% | 0.82% | 31.37% | 85.93% | 283.92% |
| Book Value per Share | 11.09 | 10.55 | 2.82 | 6.09 | 9.60 | 11.34 | 12.03 | 15.79 | 29.55 | 34.82 |
| Total Shareholders' Equity | 11.59B | 9.83B | 2.61B | 5.64B | 8.98B | 10.65B | 10.77B | 14.19B | 26.54B | 31.2B |
| Common Stock | 687.9M | 661M | 598.8M | 598.2M | 596.3M | 594.1M | 593.6M | 592.4M | 590M | 590M |
| Retained Earnings | 13.89B | 11.4B | 4.92B | 7.83B | 8.96B | 10.04B | 10.31B | 13.54B | 24.47B | 29.51B |
| Treasury Stock | -75.8M | -69.4M | -60.8M | -55.7M | -52.7M | -50.5M | -44.2M | -49.5M | 0 | 0 |
| Accumulated OCI | -8.73B | -8.74B | -6.52B | -9.51B | -4.34B | -3.84B | -4.33B | -4.32B | -2.88B | -2.83B |
| Minority Interest | 75.7M | 1.08B | 92.2M | 183.6M | 175.6M | 125.6M | 91.8M | 79.5M | 0 | 0 |
LLY Cash Flow Statement
Eli Lilly and Company (LLY) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 5.62B | 5.52B | 4.84B | 6.5B | 7.37B | 7.59B | 4.24B | 8.82B | 16.81B | 16.81B |
| Operating CF Margin % | 28.11% | 25.7% | 21.67% | 26.49% | 26.01% | 26.58% | 12.43% | 19.58% | 25.8% | - |
| Operating CF Growth % | 15.76% | -1.62% | -12.45% | 34.38% | 13.33% | 2.98% | -44.1% | 107.96% | 90.67% | 499.11% |
| Net Income | -204.1M | 3.23B | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B | 25.27B |
| Depreciation & Amortization | 1.57B | 1.61B | 1.23B | 1.32B | 1.55B | 1.52B | 1.53B | 1.77B | 2B | 2.04B |
| Stock-Based Compensation | 281.3M | 279.5M | 312.4M | 308.1M | 342.8M | 371.1M | 628.5M | 645.6M | 626M | 633.3M |
| Deferred Taxes | -787.9M | 326.8M | 62.4M | -134.5M | -802.3M | -2.19B | -2.34B | -2.68B | -1.71B | -2.79B |
| Other Non-Cash Items | 1.55B | 2.46B | -3.4B | -444.2M | 1.71B | 1.63B | 2.24B | 3.88B | 3.35B | 1.71B |
| Working Capital Changes | 3.2B | -2.38B | -1.69B | -747.4M | -1.01B | -800K | -3.06B | -5.38B | -8.09B | -6.39B |
| Change in Receivables | -357M | -10.76B | -127.2M | -1.35B | -1.28B | -299.6M | -2.45B | -2.16B | -7B | 0 |
| Change in Inventory | -253.9M | 7.8M | -258.7M | -533.4M | -235.9M | -599.7M | -1.43B | -2.51B | -4.67B | 0 |
| Change in Payables | 916.3M | -284.5M | -477.7M | 1.27B | -1.01B | 1.33B | 4.27B | 2.61B | 10.19B | 0 |
| Cash from Investing | -3.78B | 1.91B | -8.08B | -2.26B | -2.87B | -3.76B | -7.15B | -9.3B | -10.97B | -11.54B |
| Capital Expenditures | -2.16B | -1.21B | -1.35B | -2.03B | -1.31B | -1.85B | -3.45B | -5.06B | -7.84B | -8.66B |
| CapEx % of Revenue | 10.83% | 5.63% | 6.06% | 8.27% | 4.63% | 6.5% | 10.1% | 11.23% | 12.03% | - |
| Acquisitions | -882.1M | 0 | -6.94B | -849.3M | -747.4M | -327.2M | -1.04B | -947.7M | -661M | -1.72B |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -175.1M | -2B | -248.7M | 102.8M | -644.3M | -1.34B | -2.53B | -3.04B | -2.79B | -1.31B |
| Cash from Financing | 142.6M | -5.9B | -2.32B | -3.14B | -4.13B | -5.41B | 3.5B | 1.23B | -2.21B | -7.06B |
| Debt Issued (Net) | 3B | -729.3M | 4.69B | 291.6M | 501.4M | -62M | 8.65B | 8.9B | 8.05B | 4.46B |
| Equity Issued (Net) | -299.8M | -2.49B | -4.4B | -500M | -1.25B | -1.5B | -750M | -2.5B | -4.11B | -5.26B |
| Dividends Paid | -2.19B | -2.31B | -2.41B | -2.69B | -3.09B | -3.54B | -4.07B | -4.68B | -5.38B | -5.59B |
| Share Repurchases | -299.8M | -4.15B | -4.4B | -500M | -1.25B | -1.5B | -750M | -2.5B | -4.11B | -5.26B |
| Other Financing | -364.4M | -372.8M | -200.1M | -241.6M | -295.9M | -308.9M | -335M | -490.6M | -772M | -676.7M |
| Net Change in Cash | 1.95B▲ 0% | 1.46B▼ 25.2% | -5.66B▼ 487.2% | 1.32B▲ 123.3% | 161.4M▼ 87.8% | -1.75B▼ 1185.2% | 751.6M▲ 142.9% | 449.8M▼ 40.2% | 4B▲ 789.3% | 2.19B▲ 0% |
| Free Cash Flow | 3.45B▲ 0% | 2.51B▼ 27.4% | 3.48B▲ 39.0% | 4.47B▲ 28.3% | 5.39B▲ 20.5% | 4.6B▼ 14.6% | -3.15B▼ 168.5% | 414.3M▲ 113.1% | 8.97B▲ 2065.6% | 13.58B▲ 0% |
| FCF Margin % | 17.28% | 11.66% | 15.61% | 18.22% | 19.02% | 16.12% | -9.24% | 0.92% | 13.77% | 18.8% |
| FCF Growth % | -8.17% | -27.4% | 38.97% | 28.35% | 20.51% | -14.61% | -168.52% | 113.14% | 2065.58% | 1169.45% |
| FCF per Share | 3.28 | 2.42 | 3.64 | 4.67 | 5.65 | 4.84 | -3.49 | 0.46 | 9.99 | 9.99 |
| FCF Conversion (FCF/Net Income) | -27.51x | 1.71x | 0.58x | 1.05x | 1.32x | 1.21x | 0.81x | 0.83x | 0.81x | 0.54x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LLY Key Ratios
Eli Lilly and Company (LLY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1.59% | 28.63% | 122.26% | 145.32% | 74.52% | 62.67% | 48.43% | 84.26% | 101.15% | 101.17% |
| Return on Invested Capital (ROIC) | 16.52% | 27.67% | 29.94% | 30.97% | 29.03% | 27.52% | 27.79% | 33.69% | 41.82% | 41.82% |
| Gross Margin | 77.73% | 78.22% | 78.85% | 77.66% | 74.18% | 76.77% | 79.25% | 81.31% | 83.79% | 83.51% |
| Net Margin | -1.02% | 15.04% | 37.27% | 25.24% | 19.71% | 21.88% | 15.36% | 23.51% | 31.66% | 34.98% |
| Debt / Equity | 1.17x | 0.94x | 5.86x | 2.85x | 1.84x | 1.51x | 2.32x | 2.36x | 1.60x | 1.60x |
| Interest Coverage | 11.24x | 16.18x | 14.15x | 21.11x | 19.12x | 21.53x | 14.49x | 17.24x | 33.16x | 35.68x |
| FCF Conversion | -27.51x | 1.71x | 0.58x | 1.05x | 1.32x | 1.21x | 0.81x | 0.83x | 0.81x | 0.54x |
| Revenue Growth | -5.88% | 7.61% | 3.84% | 9.95% | 15.4% | 0.79% | 19.56% | 32% | 44.7% | 47.44% |
LLY SEC Filings & Documents
Eli Lilly and Company (LLY) SEC filings — annual & quarterly reports (10-K, 10-Q)
LLY Frequently Asked Questions
Eli Lilly and Company (LLY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Eli Lilly and Company (LLY) reported $72.25B in revenue for fiscal year 2025. This represents a 932% increase from $7.00B in 1996.
Eli Lilly and Company (LLY) grew revenue by 44.7% over the past year. This is strong growth.
Yes, Eli Lilly and Company (LLY) is profitable, generating $25.27B in net income for fiscal year 2025 (31.7% net margin).
Dividend & Returns
Yes, Eli Lilly and Company (LLY) pays a dividend with a yield of 0.61%. This makes it attractive for income-focused investors.
Eli Lilly and Company (LLY) has a return on equity (ROE) of 101.2%. This is excellent, indicating efficient use of shareholder capital.
Eli Lilly and Company (LLY) generated $13.58B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More LLY
Eli Lilly and Company (LLY) financial analysis — history, returns, DCA and operating performance tools
Full LLY Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates